Author Affiliations: Geriatric Research, Education, and Clinical Center, Miami Veterans Affairs Healthcare System, and Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida (Dr Levis); Department of Pediatrics, University of South Florida, Tampa (Ms Xu and Dr Krischer); and National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas (Dr Doerge).
A total of 66 randomized participants did not complete the study (23 in the soy isoflavone group and 43 in the placebo group).1 A comparable number of women in each group reported moving out of state, having a sick family member, a new job, or a desire to eat soy products as the reason to discontinue their participation. Although there was a marked difference in the proportion of participants who were no longer interested in participating in the study or were lost to follow-up (16 [19%] in the soy isoflavone group and 30 [34%] in the placebo group), we did not find any objective measures that could explain this difference.
Levis S, Xu P, Doerge DR, Krischer J. Soy Isoflavone Supplementation in Menopausal Women—Reply. Arch Intern Med. 2011;171(22):2067–2068. doi:10.1001/archinternmed.2011.583
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: